Iowa and PINT trial - SIN :: Congresso 2011 - Società Italiana di ...

Late erythropoietin for preventing red bloodcell transfusion in preterm and/or low birthweight infants (AherSM, Ohlsson A, 2010)Authors’ conclusionsLate administration of EPO reduces the use of one or more RBCtransfusions, the number of RBC transfusions per infant and the totalvolume of RBC transfused per infant.Any donor exposure is likely not avoided as most studies includedinfants who had received RBC transfusions prior to trial entry.Late EPO does not significantly reduce or increase any clinicallyimportant adverse outcomes.Further research of the use of late EPO treatment to prevent donorexposure is not indicated.30%Transfusions by Week (% Total)Research efforts should focus on1982 1989 1993limiting donor exposure during the first 20%few days of life in sick neonates, whenRBC requirements are most likely to be10%~50%required and cannot be prevented by~70%0%late EPO treatment.1 2 3 4 5 6 7 8 9 10 11 >10 12wkPostnatal Week of Life